與 仁 和 藥 業（000650.SZ） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 IVD Medical Holding Limited 華檢醫療控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1931） 全資附屬公司仁和國際達成重大戰略合作 與 仁 和 藥 業（000650.SZ）間 接 全 資 附 屬 公 司 仁 和 國 際 達 成 重 大 戰 略 合 作，於 美 國 共 同 籌 建 全 球 首 家 非 處 方 藥（OTC）垂 直 領 域RWA交 易 所。 本 公 告 乃 由 華 檢 醫 療 控 股 有 限 公 司（「本公司」或「華檢醫療」，連 同 其 附 屬 公 司 統 稱「本集團」）自 願 作 出，旨 在 向 股 東 及 潛 在 投 資 者 提 供 本 集 團 業 務 發 展 的 最 新 資 料。 一、前 言：ETHK生態戰略的系統性深化 茲提述本公司日期為2025年 ...

资料显示，仁和药业股份有限公司位于江西省南昌市红谷滩新区红谷中大道998号绿地中央广场B区元 创国际18层，成立日期1996年12月4日，上市日期1996年12月10日，公司主营业务涉及生产、销售中西 药、原料药及健康相关产品,包括口服固体制剂、口服液体制剂、大容量注射剂、小容量注射剂、外用 洗剂、搽剂、栓剂、软膏剂等剂型药品以及健康相关产品。主营业务收入构成为：药品70.25%，健康 相关产品27.79%，其他业务产品1.95%。 从仁和药业十大流通股东角度 数据显示，南方基金旗下1只基金位居仁和药业十大流通股东。南方中证1000ETF（512100）二季度增 持193.77万股，持有股数1033.67万股，占流通股的比例为0.78%。根据测算，今日浮盈赚取约351.45万 元。 9月16日，仁和药业涨5.33%，截至发稿，报6.72元/股，成交2.65亿元，换手率3.01%，总市值94.08亿 元。 南方中证1000ETF（512100）基金经理为崔蕾。 截至发稿，崔蕾累计任职时间6年315天，现任基金资产总规模949.76亿元，任职期间最佳基金回报 147.61%， 任职期间最差基金回报-15.93%。 ...

每经AI快讯，有投资者在投资者互动平台提问：子公司闪亮品牌官方公众号已发布全球首款Ulook AI眼 镜，试销售开启，并配有图文，信息是真的吗？ 仁和药业（000650.SZ）9月11日在投资者互动平台表示，本公司Ulook眼镜，目前尚未开始商业销售。 （文章来源：每日经济新闻） ...

仁和药业（000650.SZ）9月9日在投资者互动平台表示，本公司尚无ulook智能保健眼镜在世界范围内的 专利。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：ulook智能保健眼镜，作为世界首款产品，有没有在世 界范围申请专利？ ...

Core Viewpoint - Renhe Pharmaceutical Co., Ltd. is facing significant challenges in maintaining growth due to intense competition and policy regulations in the pharmaceutical industry, as evidenced by its declining revenue and net profit in the first half of 2025 [1][3]. Financial Performance - The company reported a revenue of approximately 1.975 billion yuan in the first half of 2025, a year-on-year decrease of 16.46% [1]. - The net profit attributable to shareholders was about 290 million yuan, down 13.87% year-on-year, continuing a trend of declining performance over recent years [1][3]. - Since 2019, revenue growth has stagnated, with only a slight increase of less than 500 million yuan and net profit rising by just 29 million yuan over five years [3]. Market Challenges - The decline in performance is attributed to factors such as medical insurance cost control policies, a sluggish macroeconomic environment, and fierce competition in the pharmaceutical e-commerce sector [3]. - The health-related product segment generated revenue of 549 million yuan in the first half of 2025, reflecting a 13.4% decrease, which is even higher than the decline in the pharmaceutical segment [3][4]. Acquisition Strategy - Renhe Pharmaceutical has pursued acquisitions in the health sector since 2021, acquiring 80% stakes in seven companies, aiming to create a comprehensive health product line [3]. - However, the anticipated synergies from these acquisitions have not materialized, with revenue levels reverting to pre-acquisition figures [3][4]. Integration Challenges - The difficulties in cross-industry integration have exceeded expectations, as there are significant differences in channels, operations, and brand logic between pharmaceuticals and health consumer products [4]. - The health market has become highly competitive, with both online and offline channels saturated, making it challenging for the company to stand out despite collaborations with major e-commerce platforms [4]. Financial Health - Although the net cash flow from operating activities increased by 86.14% year-on-year, this was primarily due to reduced cash payments for goods and taxes rather than profit growth [6]. - The company's monetary funds decreased by nearly 60% compared to the end of the previous year, indicating a preference for financial management over reinvestment [6]. Future Outlook - The company is working on several projects, including the digital transformation of health and disinfection product production lines, but progress has not met expectations [6]. - The challenges faced by Renhe Pharmaceutical reflect broader difficulties in the traditional OTC pharmaceutical sector, highlighting the need for comprehensive innovation across products, channels, and organizational capabilities to achieve sustainable growth in a transforming industry [6].

Core Viewpoint - Renhe Pharmaceutical's stock has shown a positive trend with a year-to-date increase of 15.51%, reflecting strong market interest and performance in the pharmaceutical sector [1][2]. Company Overview - Renhe Pharmaceutical, established on December 4, 1996, and listed on December 10, 1996, is located in Nanchang, Jiangxi Province. The company specializes in the production and sale of traditional Chinese and Western medicines, raw materials, and health-related products [1]. - The company's revenue composition includes 70.25% from pharmaceuticals, 27.79% from health-related products, and 1.95% from other business products [1]. Financial Performance - For the first half of 2025, Renhe Pharmaceutical reported a revenue of 1.975 billion yuan, a year-on-year decrease of 16.46%, and a net profit attributable to shareholders of 290 million yuan, down 13.87% compared to the previous year [2]. - The company has distributed a total of 1.962 billion yuan in dividends since its A-share listing, with 770 million yuan distributed over the last three years [3]. Shareholder Information - As of June 30, 2025, Renhe Pharmaceutical had 104,400 shareholders, a decrease of 2.76% from the previous period. The average number of tradable shares per shareholder increased by 2.84% to 12,748 shares [2]. - Major shareholders include Hong Kong Central Clearing Limited, which holds 11.4865 million shares, and Southern CSI 1000 ETF, holding 10.3367 million shares, both of which have increased their holdings [3].

人民财讯9月2日电，仁和药业（000650）9月2日在互动平台表示，公司Ulook眼镜目前尚未正式发售。 ...

Market Overview - The Chinese medicine sector rose by 0.75% on September 1, with Zhendong Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3875.53, up 0.46%, while the Shenzhen Component Index closed at 12828.95, up 1.05% [1] Top Gainers in Chinese Medicine Sector - Zhendong Pharmaceutical (300158) closed at 9.21, up 6.11% with a trading volume of 1.2136 million shares and a turnover of 1.101 billion yuan [1] - Qidi Pharmaceutical (000590) closed at 12.33, up 4.14% with a trading volume of 140,800 shares and a turnover of 174 million yuan [1] - Kangmei Pharmaceutical (600518) closed at 2.12, up 3.92% with a trading volume of 5.5195 million shares and a turnover of 1.165 billion yuan [1] Top Losers in Chinese Medicine Sector - Tianmu Pharmaceutical (600671) closed at 19.44, down 1.87% with a trading volume of 86,000 shares and a turnover of 170 million yuan [2] - Jilin Aodong (000623) closed at 20.13, down 1.66% with a trading volume of 284,000 shares and a turnover of 573 million yuan [2] - *ST Changyao (300391) closed at 4.19, down 1.64% with a trading volume of 86,000 shares and a turnover of 36.1 million yuan [2] Capital Flow Analysis - The Chinese medicine sector experienced a net outflow of 29.7085 million yuan from institutional investors, while retail investors saw a net inflow of 253 million yuan [2][3] - Notable net inflows from retail investors were observed in Yunnan Baiyao (000538) with 436.788 million yuan and in Zhongsheng Pharmaceutical (002317) with 82.0845 million yuan [3] Individual Stock Capital Flow - Yunnan Baiyao (000538) had a net inflow of 188 million yuan from institutional investors, but a net outflow of 144 million yuan from speculative funds [3] - Zhongsheng Pharmaceutical (002317) saw a net inflow of 54.7945 million yuan from institutional investors, while retail investors experienced a net outflow of 82.0845 million yuan [3] - Dong'e Ejiao (000423) had a net inflow of 53.6307 million yuan from institutional investors, with a net outflow of 40.1030 million yuan from speculative funds [3]

Company Overview - Renhe Pharmaceutical Co., Ltd. is located in Nanchang, Jiangxi Province, and was established on December 4, 1996, with its listing date on December 10, 1996 [1] - The company primarily engages in the production and sales of traditional Chinese medicine, Western medicine, raw materials, and health-related products, with a revenue composition of 70.25% from pharmaceuticals, 27.79% from health-related products, and 1.95% from other business products [1] Financial Performance - For the first half of 2025, Renhe Pharmaceutical reported a revenue of 1.975 billion yuan, a year-on-year decrease of 16.46%, and a net profit attributable to shareholders of 290 million yuan, down 13.87% year-on-year [2] - The company has cumulatively distributed 1.962 billion yuan in dividends since its A-share listing, with 770 million yuan distributed over the past three years [3] Stock Market Activity - As of September 1, Renhe Pharmaceutical's stock price increased by 2.09% to 6.35 yuan per share, with a trading volume of 150 million yuan and a turnover rate of 1.80%, resulting in a total market capitalization of 8.89 billion yuan [1] - The stock has seen a year-to-date increase of 13.19%, a decline of 3.93% over the last five trading days, a rise of 6.37% over the last 20 days, and an increase of 14.21% over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent occurrence on August 21 [1] Shareholder Information - As of June 30, 2025, Renhe Pharmaceutical had 104,400 shareholders, a decrease of 2.76% from the previous period, with an average of 12,748 circulating shares per shareholder, an increase of 2.84% [2] - Major shareholders include Hong Kong Central Clearing Limited, holding 11.4865 million shares, and Southern CSI 1000 ETF, holding 10.3367 million shares, both of which have increased their holdings compared to the previous period [3]

New Stock Offerings - Shenke Co., Ltd. (002633) has an offer period from July 29, 2025, to August 27, 2025[1] - Fushun Special Steel (600399) has an offer period from August 12, 2025, to September 10, 2025[1] - ST Gaohong (000851) has an announcement on August 26, 2025[1] Market Volatility - Great Wall Military Industry (601606) reported severe abnormal fluctuations on August 14, 2025[1] - Dongxin Co., Ltd. (688110) had an announcement on August 16, 2025, regarding market conditions[1] - Changfei Optical Fiber (601869) has an announcement dated August 27, 2025, related to market performance[1] Company Announcements - ST Dehao (002005) has an announcement on August 27, 2025, regarding its market status[1] - China Satellite (600118) announced updates on August 27, 2025[1] - ST Yizhong (603389) has an announcement dated August 26, 2025, regarding its market activities[1]